A Multifaceted Analysis of Oxycodone Addiction
Oxycodone is an important therapeutic agent in the treatment of pain. However, its excessive use in medical practice, as well as escalating rates of illegal sharing and high potential for abuse, has generated a public health crisis in North America. The objective of this review is to discuss the prevalence, clinical utility, pharmacology, pharmacokinetics/pharmacodynamics, and addictive properties of oxycodone. Oxycodone has an abuse liability that is similar to other opioids, and in some cases, even greater. The introduction to oxycodone use can come from peers at school, during the treatment of pain, or from the black market. Implementing approaches that increase training of doctors in conjunction with more information for patients, as well as employing harm reduction strategies, diversion resistant products, and drug monitoring programs, may help to reduce the risk of oxycodone misuse and abuse.
KeywordsOxycodone Addiction Abuse liability Treatment
Compliance with Ethical Standards
Conflict of Interest
Meenu Minhas and Dr. Francesco Leri declare no conflict of interest.
- American Psychiatric Association. (2013). Opioid use disorder. In Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC: American Psychiatric Publishing.Google Scholar
- Basbaum, A.I., & Jessell, T.M. (2013). Pain. In E.R. Kandel, et al. (Eds.), Principles of neural science (5th ed.). New York: McGraw Hill.Google Scholar
- Beardsley, P. M., Aceto, M. D., Cook, C. D., Bowman, E. R., Newman, J. L., & Harris, L. S. (2004). Discriminative stimulus, reinforcing, physical dependence, and antinociceptive effects of oxycodone in mice, rats, and rhesus monkeys. Experimental and Clinical Psychopharmacology, 12(3), 163–172.PubMedCrossRefGoogle Scholar
- Betourne, A., Familiades, J., Lacassagne, L., Halley, H., Cazales, M., Ducommun, B., Lassalle, J. M., Zajac, J. M., & Frances, B. (2008). Decreased motivational properties of morphine in mouse models of cancerous- or inflammatory-chronic pain: implication of supraspinal neuropeptide FF(2) receptors. Neuroscience, 157, 12–21.PubMedCrossRefGoogle Scholar
- Butler, S. F., Cassidy, T. A., Chilcoat, H., Black, R. A., Landau, C., Budman, S. H., & Coplan, P. M. (2013). Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. The Journal of Pain, 14(4), 351–358.PubMedCrossRefGoogle Scholar
- Canadian Centre on Substance Abuse (CCSA). (2015). Prescription opioids. Ottawa: Canadian Centre on Substance Abuse. Google Scholar
- Carmichael, J. P., & Lee, M. A. (2010). Symptoms of opioid withdrawal syndrome afterswitch from oxycodone to alfentanil. Journal of Pain and Symptom Management, 40(6), e4–e6.Google Scholar
- Centers for Disease Control and Prevention (CDC). (2014). Opioid painkiller prescribing. Retrieved from https://www.cdc.gov/vitalsigns/opioid-prescribing/.
- Comer, S. D., Sullivan, M. A., Vosburg, S. K., Kowalczyk, W. J., & Houser, J. (2010). Oxycodone: Laboratory study of the relationship between pain and abuse liability. Drug and AlocoholDependence, 109, 130–138.Google Scholar
- Comer, S. D., Metz, V. E., Cooper, Z. D., Kowalczyk, W. J., Jones, J. D., Sullivan, M. A., et al. (2013). Comparison of a drug versus money and drug versus drug self-administration choice procedure with oxycodone and morphine in opioid addicts. Behavioural Pharmacology, 24, 504–516.PubMedPubMedCentralCrossRefGoogle Scholar
- Coplan, P. M., Kale, H., Sandstrom, L., Landau, C., & Chilcoat, H. D. (2013). Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics. Pharmacoepidemiology and Drug Safety, 22(12), 1274–1282.PubMedPubMedCentralCrossRefGoogle Scholar
- Drug Enforcement Administration. (2014). Oxycodone. Sprinfield, Virginia: Drug Enforcement Administration.Google Scholar
- Frank, D., Mateu-Gelabert, P., Guarino, H., Bennett, A., Wendel, T., Jessell, L., & Teper, A. (2015). High risk and little knowledge: overdose experiences and knowledge among young adult nonmedical prescription opioid users. International Journal of Drug Policy, 26(1), 84–91.PubMedCrossRefGoogle Scholar
- Goodman & Gilman’s. (2001). The Pharmacological Basis of Therapeutics. In J. G. Hardman, L. E. Limbird, & A. G. Gilman (Eds.), (10th ed.). New York: McGraw-Hill.Google Scholar
- Goodman & Gilman’s. (2011). The Pharmacological Basis of Therapeutics. In L. L. Brunton, J. S. Lazo, & K. L. Parker (Eds.), (11th ed.). New York: McGraw-Hill.Google Scholar
- Gould, T. J. (2010). Addiction and cognition. Addict SciClinPract, 5(2), 4–14.Google Scholar
- Harris, S. C., Perrino, P. J., Smith, I., Shram, M. J., Colucci, S. V., Bartlett, C., & Sellers, E. M. (2013). Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasallyadministered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users. The Journal of Clinical Pharmacology, 54(4), 468–477.PubMedCrossRefGoogle Scholar
- Health Canada. (2017). New measures to inform Canadians of the risks of prescription opioids out for consultation. Retrieved from https://www.canada.ca/en/health-canada/news/2017/06/new_measures_to_informcanadiansoftherisksofprescriptionopioidsou.html.
- Hughes, A., Williams, M. R., Lipari, R. N., Bose, J., Copello, E. A., &Kroutil, L. A. (2015). Prescription Drug Use and Misuse in the United States: Results from the 2015 National Survey on Drug Use and Health. Retrieved from https://www.samhsa.gov/data/sites/default/files/NSDUH-FFR2-2015/NSDUH-FFR2-2015.htm.
- Hutchinson, M. R., Lewis, S. S., Coats, B. D., Skyba, D. A., Crysdale, N. Y., Berkelhammer, D. L., Brzeski, A., Northcutt, A., Vietz, C. M., Judd, C. M., et al. (2009). Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411. Brain BehavImmun, 23, 240–250.Google Scholar
- Johnston, L. D., O’Malley, P. M., Miech, R. A., Bachman, J. G., & Schulenberg, J. E. (2017). Monitoring the Future national survey results on drug use, 1975-2016: overview, key findings on adolescent drug use. Ann Arbor: Institute for Social Research, The University of Michigan.Google Scholar
- Jones, C.M. (2013). Trends in the distribution of selected opioids by state, US, 1999–2011. Paper presented at: National Meeting Safe State Alliance, Baltimore, MD.Google Scholar
- Kirkpatrick, S. L., & Bryant, C. D. (2015). Behavioral architecture of opioid reward and aversion in C57BL/6 substrains. Front BehavNeurosci, 8, 450.Google Scholar
- Lalovic, B., Kharasch, E., Hoffer, C., Risler, L., Liu-Chen, L.-Y., & Shen, D. D. (2006). Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. ClinPharmacol Ther, 79, 461–479.Google Scholar
- Narita, M., Nakamura, A., Ozaki, M., Imai, S., Miyoshi, K., Suzuki, M., & Suzuki, T. (2007). Comparative pharmacological profiles of morphine and oxycodone under a neuropathic pain-like state in mice: evidence for less sensitivity morphine. Neuropsychopharmacology, 33(5), 1097–1112.PubMedCrossRefGoogle Scholar
- National Institute on Drug Abuse. (2016). Monitoring the future. Retrieved from https://www.drugabuse.gov/related-topics/trends-statistics/monitoring-future
- Niikura, K., Ho, A., Kreek, M. J., & Zhang, Y. (2013). Oxycodone-induced conditioned place preference and sensitization of locomotor activity in adolescent and adult mice. PharmacolBiochemBehav, 110, 112–116.Google Scholar
- Osborne, R., Joel, S., Trew, D., & Slevin, M. (1990). Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. ClinPharmacolTher, 47, 12–19.Google Scholar
- Peacock, A., Bruno, R., Cama, E., Kihas, I., Larance, B., Lintzeris, N., ... Degenhardt, L. (2015). Jurisdictional differences in opioid use, other licit and illicit drug use, and harms associated with substance use among people who tamper with pharmaceutical opioids. Drug and Alcohol Review, 34(6), 611–622.Google Scholar
- Perrino, P. J., Colucci, S. V., Apseloff, G., & Harris, S. C. (2013). Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin® tablets compared with original OxyContin® tablets in healthy adults. Clinical Drug Investigation, 33(6), 441–449.PubMedPubMedCentralCrossRefGoogle Scholar
- Pöyhiä, R., & Kalso, E. A. (1992). Antinociceptive effects and central nervous system depression caused by oxycodone and morphine in rats. PharmacolToxicol, 70(2), 125–130.Google Scholar
- Rigg, K. K., Kurtz, S. P., & Surratt, H. L. (2012). Patterns of prescription medication diversion among drug dealers. Drugs: Education, Prevention and Policy, 19(2), 145–155.Google Scholar
- Silvasti, M., Rosenberg, P., Seppälä, T., Svartling, N., & Pitkänen, M. (1998). Comparison of analgesic efficacy of oxycodone and morphine in postoperative intravenous patient-controlled analgesia. ActaAnaesthesiolScand, 42(5), 576–580.Google Scholar
- Substance Abuse and Mental Health Services Administration (SAMHSA). (2013). National Survey on Drug use and Health 2011 and 2012. Rockville: Center for Behavioral Health Statistics and Quality.Google Scholar
- Substance Abuse and Mental Health Services Administration (SAMHSA). (2017). Prescription Drug Misuse and Abuse. Retrieved from https://www.samhsa.gov/topics/prescription-drug-misuse-abuse
- Thompson, C. M., Wojno, H., Greiner, E., May, E. L., Rice, K. C., & Selley, D. E. (2004). Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors. The Journal of Pharmacology and Experimental Therapeutics, 308(2), 547–554.PubMedCrossRefGoogle Scholar
- U.S. Cong., Senate Caucus on International Narcotics Control. (2014, May 14). National Institute on Drug Abuse. (ND. Volkow, Author) [Cong. Rept.]. Retrieved from https://www.drugabuse.gov/about-nida/legislative-activities/testimony-to-congress/2016/americas-addiction-to-opioids-heroin-prescription-drug-abuse.
- Vosburg, S. K., Eaton, T. A., Sokolowska, M., Osgood, E. D., Ashworth, J. B., Trudeau, J. J., et al. (2016). Prescription opioid abuse, prescription opioid addiction, and heroin abuse among adolescents in a recovery high school: a pilot study. Journal of Child & Adolescent Substance Abuse, 25(2), 105–112.CrossRefGoogle Scholar
- Weele, C. M., Porter-Stransky, K. A., Mabrouk, O. S., Lovic, V., Singer, B. F., Kennedy, R. T., & Aragona, B. J. (2014). Rapid dopamine transmission within the nucleus accumbens: dramatic difference between morphine and oxycodone delivery. European Journal of Neuroscience, 40(7), 3041–3054.CrossRefGoogle Scholar
- Wiebelhaus, J. M., Walentiny, D. M., & Beardsley, P. M. (2016). Effects of acute and repeated administration of oxycodone and naloxone-precipitated withdrawal on intracranial self-stimulation in rats. Behavioral Pharmacology, 356(1), 43–52.Google Scholar